The PennZone

  • Home
  • Business
  • Health
  • Education
  • Construction
  • Financial
  • Legal
  • Entertainment
  • Music

OncoBeta announces the expansion of Rhenium-SCT for non-melanoma skin cancer patients in Italy
The PennZone/10277906

Trending...
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
  • SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
Dr. Mohsen Farsad prepares to apply Rhenium-SCT Dr. Mohsen Farsad prepares to apply Rhenium-SCT
BOZEN, Italy - PennZone -- OncoBeta®, a leading medical device company specialising in innovative epidermal radioisotope therapies, has announced the expansion of Rhenium-SCT® (Skin Cancer Therapy) treatment services in Italy with the Bolzano Hospital the latest to come on board. This marks a significant advancement in the availability of non-melanoma skin cancer (NMSC) treatment options within the country.

Rhenium skin cancer therapy is an advanced radionuclide therapy that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly over the NMSC lesion, targeting cancer cells without the need for surgery.1,4

Dr. Mohsen Farsad at Bolzano Hospital has been impressed with the Rhenium-SCT device, noting, "I have witnessed impressive outcomes with several patients treated here in Italy already, and am pleased with the design of the device technology."

"Rhenium skin cancer therapy fulfills many patients' desires for a non-surgical alternative for the treatment of NMSCs  especially in relation to difficult localisations. I am pleased to continue treating suitable patients with Rhenium-SCT", adds Dr. Farsad.

Shannon D. Brown III, CCO at OncoBeta, says, "While surgical intervention remains the standard-of-care for NMSC treatment, it often leads to suboptimal outcomes. Rhenium-SCT offers a non-surgical alternative with a simple application directly to the area needed to treat, and allows patients to resume their daily activities with minimal disruption."

According to GLOBOCAN estimates, the number of new NMSC cases in Italy is projected to rise from 29,000 to 41,700 between 2022 and 2045.5 Epidemiological data for Europe shows an annual incidence rate of NMSCs at 129.3 cases per 100,000 men and 90.8 per 100,000 women. Basal cell carcinoma (BCC) accounts for approximately 15% of all diagnosed cancers in Italy, with an annual incidence of around 100 cases per 100,000 inhabitants.6

Dr. Gerhard Dahlhoff, Medical Director at OncoBeta, emphasised, "Rhenium-SCT enables targeted, non-invasive treatment of NMSCs while preserving adjacent healthy tissue. This patient-friendly approach underscores our commitment to enhancing treatment options for those affected by NMSCs."

More on The PennZone
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
  • Colbert Packaging Announces WBENC Recognition
  • SHI Cryogenics Group Launches Highest-Capacity Single-Stage Cryocoolers to Date

Rhenium-SCT is currently available in Germany, Austria, Switzerland, Italy, Spain, United Kingdom, South Africa and Australia. Rhenium-SCT will be provided to patients at Bolzano Hospital by OncoBeta's distribution partner, DSD Pharma.

About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4

The Rhenium-SCT is a painless,*1,2  single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,7 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,7 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,7,8

About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.

Find out more about the Rhenium-SCT at www.oncobeta.com

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/

More on The PennZone
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
  • Federated Hermes Premier Municipal Income Fund declares dividend
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly

Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

About DSD Pharma
DSD Pharma is a distributor for diagnostics, theranostics and radiopharmaceutical/medical devices in the field of nuclear medicine and radiopharmaceuticals. DSD Pharma offers a product portfolio developed together at the forefront of research to its customers. This ensures the safety of latest technologies for the HCP and the best available diagnosis/theranosis/therapy for the patient.

Find out more about DSD Pharma at www.dsd-pharma.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain during procedure.1,2
†
Complete tumour regression in 98.5% of lesions treated.3
‡
A treatment is considered non-invasive when no cut or break in the skin is created.9

References
  1. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48: 1511–1521.
  2. Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
  3. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.
  4. Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
  5. Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
  6. Sordi E, et al. Epidemiologia. 2024;5:1–10.
  7. Cipriani C, et al. International J Nucl Med. 2017; July:114–112.
  8. Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.
  9. Australian Therapeutic Goods Administration. Acronym and glossary of terms. Available at: https://www.tga.gov.au/resources/acronyms-and-glossary-terms. (Accessed June 2024).


Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH
Filed Under: Business, Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • The Waite Launches: A Curated Motherhood Marketplace For Every Stage
  • Affordable, High-Quality Care: Cheap Braces for Adults Available from Exeter Smiles in Reading
  • NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
  • Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
  • Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
  • Greenlight Networks to Acquire Loop Internet
  • Finding the Best AC Repair Service in Philadelphia
  • Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
  • BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
  • Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
  • Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
  • Phillie Phanatic Joins the Together We Dance Foundation's Summer Dance Team to Celebrate Inclusion
  • Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
  • Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
  • CLASS ACTION NOTICE: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Class Action
  • e4health Earns 2025-2026 Great Place To Work Certification™ for Fourth Consecutive Year
  • Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest

Popular on PennZone

  • INVESTIGATION ALERT: Berger Montague PC Investigates Coinbase Global, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NASDAQ: COIN)
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
  • Kemeny, Ramp & Renaud Expands Legal Team with Attorney Baruch Kraut
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • New Bethany Acquires Former Diocesan Headquarters to Expand Services
  • Bethany Nikitenko Honored By Legal Intelligencer with Power Player Award
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
  • JOSHWAY Launches Children's Book, "JOSHWAY and the Power of Resilience"

Similar on PennZone

  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • Franchise-Ready: Wise Business Plans Partners with Leading Franchisors to Support New Franchisees
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
  • Colbert Packaging Announces WBENC Recognition
  • Federated Hermes Premier Municipal Income Fund declares dividend
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
  • LDR Partners LP Announces Acquisition of Active Radiator, and Combination with Cincinnati Radiator and Ohio Heat Transfer, Forming the Largest U.S. Heavy Manufacturing Platform for Aluminum Industrial Heat Exchangers
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us